Fatigue · People with cancer undergoing multimodal treatment including surgery
1 finding from 1 review
Postoperative outcome · People with cancer undergoing multimodal treatment including surgery
1 finding from 1 review
Intervention not reported
Estimated total blood loss (mL) · adult women with advanced EOC undergoing cytoreductive surgery (one randomised trial available)
The intervention showed no clear difference in estimated total blood loss (mL) (low certainty).
1 finding from 1 review
Intervention not reported
Number of transfused units of red blood cell (RBC) · adult women with advanced EOC undergoing cytoreductive surgery (one randomised trial available)
The intervention showed no clear difference in number of transfused units of red blood cell (RBC) (low certainty).
1 finding from 1 review
Intervention not reported
Number of transfused units of plasma · adult women with advanced EOC undergoing cytoreductive surgery (one randomised trial available)
The intervention showed no clear difference in number of transfused units of plasma (low certainty).
1 finding from 1 review
Intervention not reported
Rate of RBC transfusion (total number of participants who required at least one unit of red blood cell transfusion) Time: perioperative and postoperative periods · adult women with advanced EOC undergoing cytoreductive surgery (one randomised trial available)
The intervention showed no clear difference in rate of RBC transfusion (total number of participants who required… (low certainty).
1 finding from 1 review
Intervention not reported
Rate of plasma transfusion (total number of participants who required at least one unit of plasma transfusion) Time: perioperative and postoperative periods · adult women with advanced EOC undergoing cytoreductive surgery (one randomised trial available)
The intervention showed no clear difference in rate of plasma transfusion (total number of participants who… (low certainty).
1 finding from 1 review
Intervention not reported
Reoperation (Number of participants with at least one reoperation) Time: perioperative periods · adult women with advanced EOC undergoing cytoreductive surgery (one randomised trial available)
It is very uncertain whether the intervention changes reoperation (Number of participants with at least one reoperation)… (very low certainty).
1 finding from 1 review
Intervention not reported
Readmission (Number of participants with at least one readmission) Time: perioperative periods) · adult women with advanced EOC undergoing cytoreductive surgery (one randomised trial available)
It is very uncertain whether the intervention changes readmission (Number of participants with at least one readmission)… (very low certainty).
1 finding from 1 review
Intervention not reported
Venous thromboembolic events (number of participants with at least one venous thromboembolic events) Time: 5‐week · adult women with advanced EOC undergoing cytoreductive surgery (one randomised trial available)
It is very uncertain whether the intervention changes venous thromboembolic events (number of participants with at least… (very low certainty).
1 finding from 1 review
Intervention not reported
Arterial thromboembolic events (number of participants with at least one venous thromboembolic events) Time: 5‐week · adult women with advanced EOC undergoing cytoreductive surgery (one randomised trial available)
It is very uncertain whether the intervention changes arterial thromboembolic events (number of participants with at least… (very low certainty).
1 finding from 1 review
Overall survival · Women with advanced (Stage II‐IV) epithelial ovarian cancer who have undergone surgery
Interferon + chemotherapy may leads to higher overall survival compared with chemotherapy alone (low certainty).
1 finding from 1 review
Nausea and vomiting · Women with advanced (Stage II‐IV) epithelial ovarian cancer who have undergone surgery
Interferon showed no clear difference in adverse event (nausea/ vomiting) compared with observation alone (low certainty).
1 finding from 1 review
Progression‐free survival · Women with advanced (Stage II‐IV) epithelial ovarian cancer who have undergone surgery
Interferon + chemotherapy may leads to higher progression‐free survival compared with chemotherapy alone (low certainty).
1 finding from 1 review
Adverse event (flu‐like symptoms) · Women with advanced (Stage II‐IV) epithelial ovarian cancer who have undergone surgery
Interferon + chemotherapy showed no clear difference in adverse event (flu‐like symptoms) compared with chemotherapy alone (low certainty).
1 finding from 1 review
Adverse effect: fatigue · Women with advanced (Stage II‐IV) epithelial ovarian cancer who have undergone surgery
Interferon + chemotherapy showed no clear difference in adverse event (fatigue) compared with chemotherapy alone (low certainty).
1 finding from 1 review
Neurotoxicity · Women with advanced (Stage II‐IV) epithelial ovarian cancer who have undergone surgery
Interferon + chemotherapy showed no clear difference in adverse event (neurotoxicity) compared with chemotherapy alone (low certainty).
1 finding from 1 review
Overall survival · Women with advanced (Stage II‐IV) epithelial ovarian cancer who have undergone surgery
Interferon showed no clear difference in overall survival compared with observation alone (low certainty).
1 finding from 1 review
Progression‐free survival · Women with advanced (Stage II‐IV) epithelial ovarian cancer who have undergone surgery
Interferon showed no clear difference in progression‐free survival compared with observation alone (low certainty).
1 finding from 1 review
Adverse event (flu‐like symptoms) · Women with advanced (Stage II‐IV) epithelial ovarian cancer who have undergone surgery
Interferon may leads to higher adverse event (flu‐like symptoms) compared with observation alone (low certainty).
1 finding from 1 review